Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.
Y J L Jansen, E A Rozeman, R Mason...
https://pubmed.ncbi.nlm.nih.gov/30923820/Actively Recruiting
Led by Rutgers, The State University of New Jersey · Updated on 2026-09-21
35
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are evaluating the use of circulating tumor DNA ctDNA to guide the duration of immune checkpoint inhibitor ICI therapy in patients with unresectable or metastatic melanoma who show disease control or response to treatment. This phase II pilot study aims to determine if ctDNA levels can help decide when to stop or shorten ICI treatment, especially after at least 6 to 12 months of therapy. The study includes patients who have responded to treatment or experienced immune-related side effects requiring treatment interruption. Participants with undetectable ctDNA and disease control will stop ICI therapy after one year. Those who have immune-related adverse events but undetectable ctDNA may also stop treatment. Patients with detectable ctDNA at the decision point will continue treatment per the investigators choice. If ctDNA becomes detectable during monitoring, restarting ICI may be considered based on imaging and clinical factors. Monitoring with imaging and ctDNA tests occurs every three months after treatment discontinuation. Throughout the study, participants will undergo regular imaging and ctDNA assessments to track disease status and treatment response. The primary outcome is the rate of sustained ctDNA negativity 12 months after stopping ICI. Secondary outcomes include progression-free survival, overall survival, and treatment-free survival one year after discontinuation. The study involves adults aged 18 to 90 with advanced melanoma and lasts until June 2029, including ongoing monitoring after treatment decisions.
CONDITIONS
A Pilot Study of ctDNA-Guided Immune Checkpoint Inhibitor Duration in Patients With Advanced Melanoma.
S
Sarah Weiss, MD
O
Olutobi Adewale
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Rutgers, The State University of New Jersey
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | ctDNA‑guided ICI duration (investigational) | Standard fixed‑duration ICI (contextual standard care) |
|---|---|---|
| What it is | An investigational pilot approach where circulating tumour DNA (ctDNA) levels guide when to stop immune checkpoint inhibitor treatment in advanced melanoma. | Current standard practice continues ICI until progression, unacceptable toxicity, or up to 2 years. |
| Role in trial | Patients in the study follow ctDNA testing to make decisions about stopping ICI when disease control is present. | Not part of the trial; represents usual clinical management outside the study. |
| Primary use | Adapts duration of ICI based on molecular disease markers to potentially shorten therapy safely. | Provides a predefined treatment duration of ICI irrespective of molecular markers. |
| How it is given or performed | Patients receive standard ICI; ctDNA is measured periodically to decide when to stop treatment. | Patients receive ICI continuously until progression, toxicity, or fixed maximum of about 2 years. |
| Evidence status | Currently being evaluated in a pilot study; effectiveness and safety not yet established. | Supported by retrospective studies and clinical experience; no consensus but common practice. |
| Important limitations | Small pilot study without randomized control; unknown whether ctDNA guidance maintains long‑term control. | Fixed durations lack personalization; discontinuation timing not tailored to molecular response. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months of monitoring after treatment decision
Participants who have disease control and undetectable ctDNA after at least 6 to 12 months of immune checkpoint inhibitor therapy may stop treatment. Those with detectable ctDNA continue treatment as decided by their doctor. Regular monitoring with imaging and ctDNA tests occurs every three months to track disease status and guide further treatment.
Visits every 3 months for imaging and ctDNA testing
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Y J L Jansen, E A Rozeman, R Mason...
https://pubmed.ncbi.nlm.nih.gov/30923820/Lydia Warburton, Leslie Calapre, Michelle R Pereira...
https://pubmed.ncbi.nlm.nih.gov/33238616/Caroline Robert, Antoni Ribas, Omid Hamid...
https://pubmed.ncbi.nlm.nih.gov/29283791/Lydia Warburton, Anna Reid, Benhur Amanuel...
https://pubmed.ncbi.nlm.nih.gov/38179171/Mathilde Amiot, Laurent Mortier, Stéphane Dalle...
https://pubmed.ncbi.nlm.nih.gov/39717261/Christopher Schroeder, Sergios Gatidis, Olga Kelemen...
https://pubmed.ncbi.nlm.nih.gov/39384805/Rutgers, The State University of New Jersey
Lead Sponsor